Navigation Links
TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
Date:4/10/2013

WASHINGTON, D.C. April 9, 2013 The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, and presented today at the American Association for Cancer Research (AACR) Annual Meeting 2013.

Data for the study was generated at the Virginia G. Piper Cancer Center Clinical Trials, a partnership of TGen and Scottsdale Healthcare.

Dr. Daniel Von Hoff, TGen Physician-In-Chief and Chief Scientific Officer of Scottsdale Healthcare's Clinical Research Institute, will present A Phase 1 Study of BIND-014, a PSMA-targeted Nanoparticle Containing Docetaxel, in Patients with Refractory Solid Tumors during an AACR session at 1 p.m. EDT today at the Washington, D.C., Convention Center, Room 146.

Dr. Von Hoff, the study's Principal Investigator, will present complete Phase 1 clinical data of BIND-014, which is produced by BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND-014 is the company's lead drug candidate.

In 28 patients with advanced or metastatic solid tumors, BIND-014 with its targeted docetaxel Accurin was shown to be generally safe and well-tolerated at the established maximum dose of 60 mg/m2. BIND-014 showed encouraging signs of anti-tumor activity, including one complete response, three partial responses and five patients with stable disease lasting at least four, 12-week-plus cycles. In addition, the pharmacokinetic (PK) profile of BIND-014 was substantially different from the published PK of conventional docetaxel.

"This Phase 1 trial has successfully established the safety and tolerability profile and maximum tolerated dose of BIND-014 in patients with advanced or metastatic solid tumor cancers," said Dr. Von Hoff, F.A.C.P., TGen's Distinguished Professor. "There is a cri
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
8. ViroPharma to Participate in Two December Healthcare Investor Conferences
9. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... joint venture with G-treeBNT (ReGenTree LLC) has retained ... trial for the orphan disorder, neurotrophic keratopathy (NK), ... eye syndrome (DES) in the U.S.  Both trials ... this year.  Each of these eye disorders was ...
(Date:4/16/2015)... ChemRar High Tech ... R&D group, and Lancet, Russian Distribution Company, ... commercialization of new medicines in ... stimulate the innovative development of the Russian ... ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , Through ...
(Date:4/16/2015)...  AnaptysBio, Inc., a leader in the ... announced the advancement of its first-in-class anti-interleukin-36 ... The Company,s anti-IL-36R therapeutic antibody, called ANB019, ... psoriasis (GPP), an orphan systemic inflammatory disease ... owned within AnaptysBio,s proprietary antibody pipeline and ...
(Date:4/16/2015)... 16, 2015 Avelas Biosciences, an in ... surgeries, announced today that it has initiated a Phase ... in women with primary, non-recurrent breast cancer undergoing surgery. ... the addition of Steven Chen , M.D., as ... label, dose escalation study will enroll up to 39 ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... LifeGen Technologies, LLC has been awarded a Phase I ... States National Institute on Aging. The project is ... adipose tissue (fat) that are regulated by a ... of Operations at LifeGen, the technology developed under ...
... Therapeutics Corporation (Nasdaq: UTHR ) announced today ... results before market open on Thursday, October 28, 2010. ... on Thursday, October 28, 2010, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
... working to provide more reliable measurement of the electrical properties ... much more accurate devices in the future. Scanning probe ... a nano-sized probe to feel the surface of a material ... small scale. The technique can also measure the electrical properties ...
Cached Biology Technology:LifeGen Technologies Awarded NIH Grant to Identify Biomarkers of a Calorie Restricted Diet in Adipose Tissue 2Measuring the electrical properties of nano-crystals 2
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... LANSING, Mich. Biodiversity feeds on itself, researchers found, as ... the case, says a Michigan State University researcher, with a ... host insect in western Michigan apple trees. A new ... behavior to favor laying eggs on apples instead of its ...
... isn,t just squeezing the middle class on land, it,s ... the Wildlife Conservation Society (WCS) and other organizations, researchers ... Eastern Africa and low fish levels. Curiously, areas ... higher fish levels. Appearing in the latest edition ...
... War, a lethal virus known as the Spanish flu ... and Asia in three convulsive waves. The year was ... victims, most of whom succumbed to severe respiratory complications ... of the first symptoms. In a new ...
Cached Biology News:Biodiversity itself begets a species cascade, researchers say 2Study says 'middle class' coral reef fish feel the economic squeeze 2Shades of 1918? New study compares avian flu with a notorious killer from the past 2Shades of 1918? New study compares avian flu with a notorious killer from the past 3Shades of 1918? New study compares avian flu with a notorious killer from the past 4Shades of 1918? New study compares avian flu with a notorious killer from the past 5
Human ICAT Affinity Purified Polyclonal Ab...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
Biology Products: